Source comparison
CJC-1295 Comparison: DAC vs. Modified GRF(1-29) vs. Native GHRH
Before selecting a peptide for growth hormone research, understand what each compound does differently at the receptor and clearance level. | Peptide | Structure | Half-Life | GH Release Pattern | Albumin Binding | Primary Use Case | Professional Assessment ||
This comparison does not assign a generated winner or score.
- Before selecting a peptide for growth hormone research, understand what each compound does differently at the receptor and clearance level.
- | Peptide | Structure | Half-Life | GH Release Pattern | Albumin Binding | Primary Use Case | Professional Assessment ||—|—|—|—|—|—|| Native GHRH(1-44) | 44 amino acids, no modifications | <7 minutes | Acute pulse, rapid clearance | None | Diagnostic GH provocation tests | Too short-lived for sustained research applications. Baseline comparison only || CJC-1295 with DAC | 30 amino acids + DAC moiety | ~8 days | Sustained tonic elevation over days | Yes (via DAC) | Long-duration GH elevation studies | Authentic long-acting compound. Ideal for protocols requiring stable IGF-1 over weeks || Modified GRF(1-29) | 29 amino acids, no DAC | ~30 minutes | Acute pulse, moderate duration | None | Pulsatile GH release studies, combination protocols | Mislabelled as 'CJC-1295 no-DAC'. Structurally closer to Sermorelin than CJC-1295 || Sermorelin (GRF 1-29) | 29 amino acids, unmodified | ~10 minutes | Acute pulse, very rapid clearance | None | Clinical GH deficiency therapy (historical) | No DPP-IV
- The 'Bottom Line' column exists because peptide selection isn't about preference. It's about matching pharmacokinetics to protocol design. If your study measures cumulative IGF-1 changes over 14–21 days, CJC-1295 with DAC is the only rational choice. If you're studying synergistic GH pulse amplification with GHRP analogs, modified GRF(1-29) is the tool. Native GHRH is a reference standard, not a research reagent.